Medir


MEDIR is a specialty pharmaceutical company, seeking to address the areas of high unmet medical needs in:
1. inducing mild sedation in a safe, convenient and needle free way; and
2. offering a treatment for acute epileptic seizure control outside a hospital setting, that is fast, efficacious and easy adminstered.
The company has developed nasal sprays (trademark: Nazolam / Nasolam) containing midazolam. The EMA recommended authorisation of Nasolam in the EU in January 2022. 

Device picture: property and courtesy of Aptar Pharma

Nazolam / Nasolam news

EMA recommends approval of Nasolam in the EU

https://www.ema.europa.eu/en/documents/referral/nasolam-article-294-referral-ema-recommends-authorisation-nasolam-midazolam-nasal-spray-eu_en.pdf

Read More

Nazolam / Nasolam news

In a survey among epileptics/care givers, it was concluded that the nasal spray has been received with a lot of…

Read More

Contact us